- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.04. | iSpecimen Inc. - 8-K, Current Report | 13 | SEC Filings | ||
| 09.04. | iSpecimen implements direct shipping model for biospecimens | 3 | Investing.com | ||
| 09.04. | iSpecimen Inc.: iSpecimen Achieves 85% Reduction in Human Biospecimen Shipping Time | 350 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - April 9, 2026) - iSpecimen (NASDAQ: ISPC), an online marketplace for human biospecimens, has implemented a streamlined shipping model that enables direct... ► Artikel lesen | |
| 01.04. | iSpecimen Inc. - 10-K, Annual Report | 12 | SEC Filings | ||
| 31.03. | iSpecimen Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| ISPECIMEN Aktie jetzt für 0€ handeln | |||||
| 16.03. | iSpecimen-Aktie im Aufwind nach Lieferung von 500 Grippeproben für Forschungsprojekt | 7 | Investing.com Deutsch | ||
| 16.03. | iSpecimen Inc.: iSpecimen Achieves Rapid Procurement Milestone for Influenza Research | 305 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - March 16, 2026) - iSpecimen Inc. (NASDAQ: ISPC) (the "Company"), a leading provider of human biospecimens for research, is proud to announce recent milestones... ► Artikel lesen | |
| 13.03. | Fehlendes Quorum: Jährliche Hauptversammlung von iSpecimen erneut vertagt | 3 | Investing.com Deutsch | ||
| 13.03. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.03. | iSpecimen Inc.: iSpecimen Launches AI Agent Revolutionizing Biospecimen Matching | 360 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - March 12, 2026) - iSpecimen Inc. (NASDAQ: ISPC) (the "Company"), a leading technology marketplace connecting researchers with biospecimen suppliers, today... ► Artikel lesen | |
| 18.02. | iSpecimen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.02. | iSpecimen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.02. | iSpecimen Inc.: iSpecimen Announces Milestone 2: System Integration and Marketplace Activation Complete | 393 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ: ISPC) today announced the successful completion of Milestone 2, System Integration and Marketplace Activation... ► Artikel lesen | |
| 06.02. | iSpecimen Inc.: iSpecimen Achieves Rapid Procurement Milestone for Influenza Research | 341 | Newsfile | Lexington, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ: ISPC), a leading provider of human biospecimens for research, is proud to announce recent milestones that... ► Artikel lesen | |
| 27.01. | iSpecimen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.01. | E.F. Hutton arrangiert Privatplatzierung: iSpecimen erhält 5,5 Millionen US-Dollar | 5 | Investing.com Deutsch | ||
| 06.01. | E.F. Hutton raises $5.5 million for iSpecimen in private placement | 5 | Investing.com | ||
| 05.01. | iSpecimen vertagt Jahreshauptversammlung mangels Beschlussfähigkeit auf den 23. Januar | 2 | Investing.com Deutsch | ||
| 02.01. | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.12.25 | iSpecimen Inc (ISPC) Stock Surged 42% After-Hours: Here's The News Behind The Move | 3 | Benzinga.com |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,20 | -1,43 % | BioNTech: Gute News - doch reicht das? | Nach dem heftigen Rücksetzer bei BioNTech, nachdem bekannt wurde, dass die beiden Gründer Ugur Sahin und Özlem Türeci bis spätestens Ende des Jahres das Unternehmen verlassen werden, arbeitet die Aktie... ► Artikel lesen | |
| QIAGEN | 34,795 | -0,59 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| AMGEN | 300,75 | -0,36 % | Pfizer, Amgen among 22 firms to expand in Hong Kong: SCMP | ||
| NOVAVAX | 7,370 | -1,86 % | Is Shah Capital's Criticism of Novavax Fair? A Wall Street Analyst Weighs In | ||
| BIOGEN | 155,12 | +2,95 % | Notable analyst calls this week: Tesla, Qualcomm and Biogen among top picks | ||
| ILLUMINA | 113,16 | -0,96 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,880 | -2,85 % | 2 Billion Reasons to Love CRISPR Therapeutics Right Now | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 22,085 | +4,92 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,040 | +2,46 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,800 | -0,33 % | Better Long-Term Buy: Eli Lilly or Viking Therapeutics? | ||
| MAINZ BIOMED | 0,487 | 0,00 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| INTELLIA THERAPEUTICS | 12,360 | -2,68 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 46,380 | -2,31 % | Here's What TD Cowen Thinks About Tempus AI Inc (TEM) Stock | ||
| COSCIENS BIOPHARMA | 1,540 | +1,99 % | COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on the development of natural... ► Artikel lesen |
Das Unternehmen ISPECIMEN INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,132 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISPECIMEN INC finden Sie auf Wallstreet Online.